Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.
Twenty-three patients with heptocellular carcinoma were treated with m-AMSA at a dose of 120 mg/m2 iv repeated at 4-week intervals. Toxicity was primarily hematologic. Partial responses occurred in two of 14 previously treated patients and in one of nine previously untreated patients. The overall activity of m-AMSA in patients with hepatocellular carcinoma appears minimal.